Biogen (BIIB) Operating Expenses (2009 - 2026)
Biogen (BIIB) posted quarterly Operating Expenses of $2.6 billion for Q2 2026, up 36.92% year-over-year from $1.9 billion in Q2 2025, and up 23.98% quarter-over-quarter from $2.1 billion in Q1 2026.
Biogen (BIIB) Operating Expenses (2009 - 2026) Analysis & Trends
Biogen's Operating Expenses history runs 18 years deep, the most recent figure standing at $2.6 billion for Q2 2026.
- In Q2 2026, Operating Expenses rose 36.92% year-over-year to $2.6 billion; the TTM figure through Jun 2026 stood at $9.0 billion (up 9.97% YoY), while the FY2025 annual figure was $8.3 billion, up 7.26% from the prior year.
- Operating Expenses for Q2 2026 stood at $2.6 billion, up from $2.1 billion in the prior quarter.
- The five-year high for Operating Expenses was $2.7 billion in Q3 2023, with the low at $1.1 billion in Q3 2022.
- The 5-year median for Operating Expenses is $2.0 billion (2023), against an average of $2.0 billion.
- The sharpest annual moves came in 2022 and 2023: Operating Expenses plunged 54.28% in 2022, then soared 134.88% in 2023.
- Biogen's Operating Expenses stood at $1.9 billion in 2022, then rose by 7.96% to $2.1 billion in 2023, then advanced by 3.27% to $2.2 billion in 2024, then gained by 7.96% to $2.3 billion in 2025, then rose by 11.48% to $2.6 billion in 2026.
- Business Quant data shows BIIB's Operating Expenses at $2.6 billion in Q2 2026, $2.1 billion in Q1 2026, and $2.3 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 10.12 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 10.56 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 12.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 6.09 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 9.70 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 6.54 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 18.20 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 6.68 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -7.60 Bn |
| 10 | Biogen | 31.73 Bn | 30.45 Bn | 1.96 Bn | 2.60 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.60 Bn |
| Mar 31, 2026 | 2.10 Bn |
| Dec 31, 2025 | 2.34 Bn |
| Sep 30, 2025 | 1.98 Bn |
| Jun 30, 2025 | 1.90 Bn |
| Mar 31, 2025 | 2.12 Bn |
| Dec 31, 2024 | 2.16 Bn |
| Sep 30, 2024 | 2.01 Bn |
| Jun 30, 2024 | 1.77 Bn |
| Mar 31, 2024 | 1.83 Bn |
| Dec 31, 2023 | 2.09 Bn |
| Sep 30, 2023 | 2.67 Bn |
| Jun 30, 2023 | 1.75 Bn |
| Mar 31, 2023 | 2.02 Bn |
| Dec 31, 2022 | 1.94 Bn |
| Sep 30, 2022 | 1.14 Bn |
| Jun 30, 2022 | 1.32 Bn |
| Mar 31, 2022 | 2.18 Bn |
| Dec 31, 2021 | 2.33 Bn |
| Sep 30, 2021 | 2.49 Bn |